Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $800.00 by Analysts at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target cut by Wells Fargo & Company from $825.00 to $800.00 in a report issued on Thursday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

A number of other research firms have also commented on REGN. Piper Sandler assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, TD Cowen lifted their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $825.68.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $707.06 on Thursday. The stock has a market cap of $74.75 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. The company has a current ratio of 4.15, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $756.81 and its 200-day moving average is $735.17. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business posted $8.22 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC grew its holdings in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC grew its stake in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. Finally, Rexford Capital Inc. grew its stake in Regeneron Pharmaceuticals by 5.5% in the 4th quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both profit and sales: non‑GAAP EPS $9.47 vs. consensus ~ $9.10 and revenue ~$3.6B (+19% y/y), driven by Dupixent strength. This is the primary catalyst supporting the stock today. Regeneron beats quarterly results estimates on strong Dupixent demand
• Positive Sentiment: Board approved up to $3.0B share repurchase program — a direct return‑of‑capital move that typically supports the share price. Analysts and headlines flagged the buyback alongside the earnings beat. Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
• Positive Sentiment: Quarterly cash dividend declared ($0.94 per share, record May 20, payable June 4) — adds a modest yield and supports income‑oriented holders.
• Neutral Sentiment: Pipeline updates: multiple C5 program milestones (PNH enrollment completion) and positive phase III data for cemdisiran in gMG with regulatory submissions underway — bullish for long‑term valuation but timing and commercial execution remain uncertain. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation
• Neutral Sentiment: GAAP net income fell ~10% to $727M despite revenue growth (non‑GAAP metrics look stronger) — suggests some one‑time items/adjustments that investors should parse in the quarter’s detail. Regeneron Q1 2026 net income falls 10% to $727m
• Negative Sentiment: EYLEA concerns: U.S. sales of high‑dose EYLEA came in below expectations and total EYLEA sales declined y/y, highlighting intensifying competition in the retina market — this is why shares slipped immediately after the print for some investors. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug
• Negative Sentiment: Several firms trimmed price targets and forecasts post‑earnings (RBC, Wells Fargo, Truist, Barclays among others) — analysts cite mix shifts and competitive risk, which could cap near‑term upside despite the buyback. Analysts Cut Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.